This DMF-mediated mechanism of inhibition of NF-κB has been demonstrated by Kastrati et al. in breast cancer cells and, added to the activation of the Nfr2 cytoprotective pathway, may suggest an anti-tumor activity of DMF [22]. The gene discussed is NFKB1; the disease is breast carcinoma.